Published in Rev Urol on January 01, 2005
Cancer incidence in the U.S. military population: comparison with rates from the SEER program. Cancer Epidemiol Biomarkers Prev (2009) 1.03
Is repeat biopsy for isolated high-grade prostatic intraepithelial neoplasia necessary? Rev Urol (2007) 0.78
A pilot study to investigate if New Zealand men with prostate cancer benefit from a Mediterranean-style diet. PeerJ (2015) 0.77
Pathological Correlation between Number of Biopsies and Radical Surgery: Does It Make a Difference to Final Pathology? Curr Urol (2013) 0.75
A histopathological study of prostate lesions in Lagos, Nigeria: A private practice experience. Niger Med J (2016) 0.75
Cancer statistics, 2004. CA Cancer J Clin (2004) 15.72
High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo (1995) 3.25
The focus of "atypical glands, suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol (1997) 2.98
The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol (1993) 2.95
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80
Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy. Am J Clin Pathol (1989) 2.14
Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol (1986) 2.01
Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol (2001) 1.87
Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85
Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol (1993) 1.82
Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer (1987) 1.79
Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol (2000) 1.66
OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology (1995) 1.56
Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology (2000) 1.53
Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res (2002) 1.39
The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer (1991) 1.39
Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol (1995) 1.33
Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. J Urol (2001) 1.33
Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res (1985) 1.32
Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol (1991) 1.31
Topography of neovascularity in human prostate carcinoma. Cancer (1995) 1.18
High-grade prostatic intraepithelial neoplasia. Rev Urol (2004) 1.18
Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol (2001) 1.16
Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol (1996) 1.15
Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res (2002) 1.14
Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene (2003) 1.11
Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology (1999) 1.10
Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? Urology (2001) 1.10
The significance of prostatic intra-epithelial neoplasia. Br J Urol (1995) 1.09
The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol (1995) 1.09
Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am J Pathol (1991) 1.08
Repeat prostate needle biopsy: who needs it? J Urol (1995) 1.06
Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology (1997) 1.02
Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res (2001) 1.02
Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. Urology (1991) 1.02
Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk. J Urol (2001) 1.01
Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J Urol (1996) 0.99
Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J Urol (2003) 0.95
Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer (1999) 0.95
Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol (1993) 0.95
Atypical adenomatous hyperplasia of the prostate. Relationship with carcinoma in 217 whole-mount radical prostatectomies. Am J Surg Pathol (1995) 0.94
Differential immunolocalization of estrogen receptor alpha and beta in rat ovary and uterus. J Mol Endocrinol (1999) 0.93
Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep (2003) 0.90
Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer. Prostate (2004) 0.89
Use of transrectal ultrasound and prostate-specific antigen in diagnosis of prostatic intraepithelial neoplasia. Urology (1989) 0.89
Inverted (Hobnail) high-grade prostatic intraepithelial neoplasia (PIN): report of 15 cases of a previously undescribed pattern of high-grade PIN. Am J Surg Pathol (2001) 0.89
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol (1995) 0.88
Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention. Eur Urol (1999) 0.88
Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race. Cancer (2001) 0.86
Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy. Urology (1998) 0.84
Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration. Urology (1996) 0.84
Prevalence of prostatic intra-epithelial neoplasia (PIN) in biopsies from hospital practice and pilot screening: clinical implications. Prostate Cancer Prostatic Dis (1997) 0.82
Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens. Urology (1997) 0.82
High grade prostatic intraepithelial neoplasia is a disease. Curr Urol Rep (2001) 0.81
Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens. Urology (1997) 0.81
Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen. Int Braz J Urol (2005) 0.81
Prostatic intraepithelial neoplasia: a lesion that may be confused with cancer on prostatic ultrasound. J Urol (1989) 0.80
Glycoprotein A-80 in the human prostate: immunolocalization in prostatic intraepithelial neoplasia, carcinoma, radiation failure, and after neoadjuvant hormonal therapy. Urology (2003) 0.78
Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. Anat Pathol (1998) 0.77
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology (2005) 1.37
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials (2003) 1.33
High-grade prostatic intraepithelial neoplasia. Rev Urol (2004) 1.18
Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin (2014) 1.10
Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA. BJU Int (2004) 1.04
Attitudes and use of complementary medicine in men with prostate cancer. J Urol (2002) 1.02
Radiation therapy failure in prostate cancer patients: risk factors and methods of detection. Rev Urol (2002) 0.96
Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol (2005) 0.90
Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin (2013) 0.88
Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol (2011) 0.87
Hormonal therapy for prostate cancer. Rev Urol (2006) 0.85
Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol (2002) 0.85
Testosterone replacement in men with andropause: an overview. Rev Urol (2004) 0.84
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology (2002) 0.83
A neurocomputational model for prostate carcinoma detection. Cancer (2003) 0.83
Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. Rev Urol (2003) 0.82
Chemoprevention strategies in the prostate: an overview. Rev Urol (2002) 0.81
Assays for complexed prostate-specific antigen and other advances in the diagnosis of prostate cancer. Rev Urol (2003) 0.79
Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer. Rev Urol (2004) 0.78
Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. Urology (2003) 0.78
Early diagnosis and staging of prostate cancer. Rev Urol (2003) 0.77
Best of the 2012 AUA Annual Meeting: Highlights From the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA. Rev Urol (2012) 0.75
Urology Update from Jackson Hole: Highlights from the 3rd Annual Jackson Hole Summer Urologic Conference July 28-August 3, 2001, Jackson Hole, WY. Rev Urol (2002) 0.75
Challenges with luteinizing hormone-releasing hormone agonists: flare and surge. Rev Urol (2004) 0.75
Management of localized prostate cancer. Rev Urol (2004) 0.75
Best of the AUA Annual Meeting: Highlights From the 2010 American Urological Association Meeting, May 29-June 3, 2010, San Francisco, CA. Rev Urol (2010) 0.75
Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA. Rev Urol (2013) 0.75
Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy. Rev Urol (2002) 0.75
Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? Urology (2002) 0.75
Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology (2002) 0.75
Testosterone replacement therapy for a man with prostate cancer. Rev Urol (2004) 0.75